文献速递瓣膜病与结构性心脏病

利洛纳塞治疗复发性心包炎的II期临床试验疗效与安全性

Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial.
PubMed 文献 · Heart · 2020-11-23

这项多中心开放标签II期研究纳入25例复发性心包炎成人患者,给予利洛纳塞负荷320mg皮下注射后每周160mg维持6周,可选延长18周。有症状患者疼痛评分和CRP快速下降,激素依赖患者中84.6%成功停用激素,安全性与已知特征一致。

要点

  • 利洛纳塞可快速降低复发性心包炎患者疼痛和CRP,中位CRP正常化时间9天
  • 基线使用激素的患者中84.6%在延长治疗期成功停用激素且无复发
  • 安全性方面1例严重不良事件导致停药,与已知安全性特征一致

核心结论

  • 利洛纳塞可快速且持续改善复发性心包炎患者的疼痛、炎症和健康相关生活质量。
  • 糖皮质激素可成功减量或停用,安全性特征与已知一致。

研究设计与样本

  • 多中心、开放标签II期临床研究,纳入25例成人特发性或心包切开术后复发性心包炎患者。
  • 患者接受利洛纳塞320mg皮下负荷后160mg每周皮下维持,6周基础治疗期后可选18周延长治疗期。
  • 有症状患者定义:≥2次心包炎复发;激素依赖患者定义:既往≥2次复发。

主要发现

  • 有症状患者疼痛数字评分从基线4.5降至基础治疗期末0.7。
  • CRP从基线4.62 mg/dL降至基础治疗期末0.38 mg/dL,中位CRP正常化时间9天。
  • 心包炎表现全部缓解,有症状患者健康相关生活质量平均评分改善。
  • 基线使用激素并完成延长治疗期的13例患者中,11例(84.6%)停用激素,2例减量,CRP和疼痛评分保持低水平且无复发。
  • 1例严重不良事件导致利洛纳塞停药。

临床怎么用

  • 对特发性或心包切开术后复发性心包炎,可考虑利洛纳塞以快速控制疼痛和炎症。
  • 对激素依赖性复发性心包炎,利洛纳塞有助于减停糖皮质激素。

局限性

  • 开放标签设计,无对照组,样本量小(25例)。
  • 研究为II期探索性试验,疗效和安全性需更大规模随机对照研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Recurrent pericarditis (RP) incurs significant morbidity. Rilonacept inhibits both interleukin-1 alpha (IL-1α) and IL-1β; these cytokines are thought to play a major role in RP. This phase II study evaluated rilonacept efficacy and safety in RP. METHODS: This multicentre, open-label study enrolled adult patients with idiopathic or postpericardiotomy RP, symptomatic (≥2 pericarditis recurrences) or corticosteroid (CS) dependent (≥2 recurrences prior).Patients received rilonacept 320 mg SC load/160 mg SC weekly maintenance in a 6-week base treatment period (TP) followed by an optional 18-week on-treatment extension period (EP) (option to wean background therapy). RESULTS: Outcomes: pericarditis pain (numeric rating scale (NRS)) and inflammation (C reactive protein (CRP)) for symptomatic patients; disease activity after CS taper for CS-dependent patients. SECONDARY OUTCOMES: health-related quality of life (HRQOL), pericarditis manifestations and additional medications. 25 unique patients enrolled, while 23 completed the EP (seven colchicine failures and five CS failures). In symptomatic patients, NRS and CRP decreased; response was observed after first rilonacept dose. NRS decreased from 4.5 at baseline to 0.7, and CRP decreased from 4.62 mg/dL at baseline to 0.38 mg/dL at end of TP. Median time to CRP normalisation: 9 days. Pericarditis manifestations resolved. 13 patients on CS at baseline completed the EP; 11 (84.6%) discontinued CS, and 2 tapered; CRP and NRS remained low without recurrence. Mean HRQOL scores improved in symptomatic patients. One serious adverse event (SAE) resulted in discontinuation of rilonacept. CONCLUSIONS: Rilonacept led to rapid and sustained improvement in pain, inflammation (CRP and pericarditis manifestations) and HRQOL. CSs were successfully tapered or discontinued; safety was consistent with known rilonacept safety profile. TRIAL REGISTRATION NUMBER: NCT03980522.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Klein AL, Lin D, Cremer PC, et al. Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial. Heart. 2020. PMID: 33229362. doi:10.1136/heartjnl-2020-317928

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。